Joseph M. Miller Sells 61,859 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the transaction, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. The trade was a 8.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Aurinia Pharmaceuticals Stock Performance

AUPH opened at $8.67 on Thursday. The company’s 50 day moving average is $8.13 and its 200 day moving average is $7.86. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -57.80 and a beta of 1.22. Aurinia Pharmaceuticals Inc. has a 12-month low of $4.71 and a 12-month high of $10.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. SBI Securities Co. Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth $25,000. GF Fund Management CO. LTD. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $27,000. Tower Research Capital LLC TRC increased its position in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $31,000. Finally, Natixis purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $49,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.